Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three Kennedy Trust for Rheumatology Research (KTRR) Fellows at the Kennedy Institute were recently awarded prestigious funding awards, highlighting the success of the KTRR programme in supporting outstanding investigators launch their independent research career.

The KTRR Senior Research Fellowship programme creates a platform for early stage scientists to launch an independent research career; it has also enabled the Kennedy Institute to recruit bright young investigators from across the globe. 

“The KTRR provided a great opportunity for the Institute to recruit the best and brightest after the move to Oxford.” Says Professor Michael Dustin, Director of Research of the Kennedy Institute. “We are all excited by their progress in establishing their research programs and development as independent scientists.”

The five-year fellowships provide awardees with a generous funding package and strong mentorship, embedded within the institute’s outstanding research environment. 

The first of these fellowships was awarded in 2013 to Dr Tal Arnon, who has subsequently received a Wellcome Trust Investigator award in 2014.

Three more Senior Research Fellowships were awarded in 2016, to Dr Jelena Bezbradica Mirkovic, Dr Anjali Kusumbe, and Dr Audrey Gerard.

Dr Kusumbe received an MRC Career Development Fellowship in 2017 and earlier this year Dr Gerard won a BBSRC New Investigator Grant.

More recently, Dr Jelena Bezbradica Mirkovic won an MRC New Investigator Research Grant to study the biology of FAM26F protein in myeloid cells.

She says: “We are grateful to the Kennedy Trust for their support in establishing our independent research programmes. My group is investigating how innate immune cells, such as macrophages and dendritic cells, integrate tissue-derived inflammatory signals to initiate an appropriate effector response to infection or to sterile injury. The MRC New Investigator Grant is an exciting opportunity to investigate what role a poorly characterized protein, FAM26F, plays in the inflammatory process.”

 

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8th October 2026.

Adam Croft appointed Norman Collisson Professor of Musculoskeletal Science

This appointment brings a further focus to linking rheumatology discovery science and clinical trials in NDORMS, strengthening translational rheumatology research across the department to deliver transformative treatments for patients with inflammatory arthritis.

Researchers funded to cure – rather than manage – inflammatory disease

Researchers from the Kennedy Institute of Rheumatology will join international partners in a bid to transform how chronic inflammatory disease is treated.

Arthritis origins may begin before birth, study finds

Researchers at the Kennedy Institute have discovered that some joints may be more susceptible to inflammatory arthritis before birth, offering new insight into why rheumatoid arthritis attacks particular joints while sparing others.

Mark Coles receives funding to tackle viral threats

Professor Mark Coles is leading one of three innovative University of Oxford research projects that have secured funding through the UK's Advanced Research and Invention Agency (ARIA) to transform how we protect against respiratory viruses.

Natural compound may help boost vaccine responses in older adults

NDORMS researchers have found that a naturally occurring compound called spermidine may help improve vaccine responses in some older adults by reducing signs of immune system ageing.